An inhibitory effect on at least one member selected from the group consisting of Akt kinase, Rsk kinase and S6K kinase, and / or cell proliferation inhibitory effect. Further, the present invention provides a medicament useful for the prevention and / or treatment of diseases associated with at least one selected from the group consisting of Akt kinase, Rsk kinase and S6K kinase according to the inhibitory action, particularly cancer. In the formula (I), R 1 is a 4 to 6 member monocyclic group having 1 to 3 heteroatoms selected from N, S and O, which may have a substituent group An unsaturated heterocycle group； R 2 represents a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C 1 -C 6 alkyl group, a C 1 -C 6 haloalkyl group, A C2-C6 alkenyl group or a C2-C6 alkynyl group； R 3 , R 4 and R 5 are the same or different and represent a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C 1 -C 6 alkyl group, a C 1 -C 6 haloalkyl group, a C 2 -C 6 alkenyl group, C6 alkynyl group； Or R 3 and R 4 together with the nitrogen atom to which they are attached form a 4- to 6-membered monocyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S and O and R 5 is the same or carry, A halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group or a C2-C6 alkynyl group； Or R 4 and R 5 form a 4 to 6 membered monocyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S and O together with the nitrogen atom to which they are bonded and the adjacent carbon atom, and R 3 is A halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group and a C2-C6 alkynyl group； R 6 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C 1 -C 6 alkyl group, a C 1 -
